Literature DB >> 21705349

A Brugada syndrome mutation (p.S216L) and its modulation by p.H558R polymorphism: standard and dynamic characterization.

Stefano Marangoni1, Chiara Di Resta, Marcella Rocchetti, Lucio Barile, Riccardo Rizzetto, Aurora Summa, Stefano Severi, Elena Sommariva, Carlo Pappone, Maurizio Ferrari, Sara Benedetti, Antonio Zaza.   

Abstract

AIMS: The Na(+) channel mutation (p.S216L), previously associated with type 3 long-QT syndrome (LQT3) phenotype, and a common polymorphism (p.H558R) were detected in a patient with an intermittent Brugada syndrome (BS) ECG pattern. The study was aimed to assess the p.S216L electrical phenotype, its modulation by p.H558R, and to identify abnormalities compatible with a mixed BS-LQT3 phenotype. METHODS AND
RESULTS: The mutation was expressed alone (S216L channels), or in combination with the polymorphism (S216L-H558R channels), in a mammalian cell line (TSA201). Functional analysis included standard voltage clamp and dynamic clamp with endo- and epicardial action potential waveforms. Expression of S216L channels was associated with a 60% reduction in maximum Na(+) current (I(Na)) density, attributable to protein misfolding (rescued by mexiletine pretreatment) and moderate slowing of inactivation. I(Na) density partially recovered in S216L-H558R channels, but I(Na) inactivation and its recovery were further delayed. The persistent component of I(Na) (I(NaL)) was unchanged. Under dynamic clamp conditions, I(Na) decreased in S216L channels and displayed a 'resurgent' component during late repolarization. In S216L-H558R channels, I(Na) density partially recovered and did not display a resurgent component. I(Na) changes during dynamic clamp were interpreted by numerical modelling.
CONCLUSION: The BS pattern of p.S216L might result from a decrease in I(Na) density, which masked gating abnormalities that might otherwise result in a LQT phenotype. The p.H558R polymorphism decreased p.S216L expressivity, partly by lessening p.S216L effects and partly through the induction of further gating abnormalities suitable to blunt p.S216L effects during repolarization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705349     DOI: 10.1093/cvr/cvr142

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  25 in total

1.  Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing.

Authors:  David J Tester; Argelia Medeiros-Domingo; Melissa L Will; Carla M Haglund; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

2.  Dynamics of the late Na(+) current during cardiac action potential and its contribution to afterdepolarizations.

Authors:  Balazs Horvath; Tamas Banyasz; Zhong Jian; Bence Hegyi; Kornel Kistamas; Peter P Nanasi; Leighton T Izu; Ye Chen-Izu
Journal:  J Mol Cell Cardiol       Date:  2013-09-06       Impact factor: 5.000

Review 3.  The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?

Authors:  Dawood Darbar
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

4.  Electrophysiological characterization of a large set of novel variants in the SCN5A-gene: identification of novel LQTS3 and BrS mutations.

Authors:  Beatriz Ortiz-Bonnin; Susanne Rinné; Robin Moss; Anne K Streit; Michael Scharf; Katrin Richter; Anika Stöber; Arne Pfeufer; Gunnar Seemann; Stefan Kääb; Britt-Maria Beckmann; Niels Decher
Journal:  Pflugers Arch       Date:  2016-06-11       Impact factor: 3.657

Review 5.  Dysfunctional Nav1.5 channels due to SCN5A mutations.

Authors:  Dan Han; Hui Tan; Chaofeng Sun; Guoliang Li
Journal:  Exp Biol Med (Maywood)       Date:  2018-05-27

6.  Genetics can contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification.

Authors:  Elena Sommariva; Carlo Pappone; Filippo Martinelli Boneschi; Chiara Di Resta; Maria Rosaria Carbone; Erika Salvi; Pasquale Vergara; Simone Sala; Daniele Cusi; Maurizio Ferrari; Sara Benedetti
Journal:  Eur J Hum Genet       Date:  2013-01-16       Impact factor: 4.246

7.  Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing.

Authors:  Lia Crotti; Cherisse A Marcou; David J Tester; Silvia Castelletti; John R Giudicessi; Margherita Torchio; Argelia Medeiros-Domingo; Savastano Simone; Melissa L Will; Federica Dagradi; Peter J Schwartz; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2012-07-25       Impact factor: 24.094

8.  Brugada syndrome disease phenotype explained in apparently benign sodium channel mutations.

Authors:  Malcolm Hoshi; Xi X Du; Krekwit Shinlapawittayatorn; Haiyan Liu; Sam Chai; Xiaoping Wan; Eckhard Ficker; Isabelle Deschênes
Journal:  Circ Cardiovasc Genet       Date:  2014-02-26

9.  Brugada syndrome risk loci seem protective against atrial fibrillation.

Authors:  Laura Andreasen; Jonas B Nielsen; Stine Darkner; Ingrid E Christophersen; Javad Jabbari; Lena Refsgaard; Jens J Thiis; Ahmad Sajadieh; Arnljot Tveit; Stig Haunsø; Jesper H Svendsen; Nicole Schmitt; Morten S Olesen
Journal:  Eur J Hum Genet       Date:  2014-03-26       Impact factor: 4.246

Review 10.  The late Na+ current--origin and pathophysiological relevance.

Authors:  Antonio Zaza; Marcella Rocchetti
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.